Know Cancer

forgot password

A Randomized, Blinded, Phase 2 Dose-Ranging Study Of BMS-936558 (MDX-1106) In Subjects With Progressive, Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Phase 2
18 Years
Open (Enrolling)
Renal Cell Carcinoma

Thank you

Trial Information

A Randomized, Blinded, Phase 2 Dose-Ranging Study Of BMS-936558 (MDX-1106) In Subjects With Progressive, Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email Please visit for more information on clinical trial participation.

Inclusion Criteria:

- Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component

- Previous treatment with at least one anti-angiogenic agent

- Progressed within 6 months of study enrollment

- Subjects should not have had more than 3 prior treatments for locally advanced or
metastatic disease

- Must have available tumor tissue for submission

- Subjects must also meet various laboratory parameters for inclusion

Exclusion Criteria:

- Subjects with any active autoimmune disease or a history of known autoimmune disease

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Progression free survival as measured by tumor assessments (radiographic scans) and the collection of death data. It will be compared to the doses given across the 3 treatment arms to see if a dose response exists.

Outcome Time Frame:

Tumor assessments (radiographic scans) will be done every 6 weeks from randomization for the first 12 months, then every 12 weeks until progression is documented. Subjects will be assessed for survival every 3 months.

Safety Issue:


Principal Investigator

Bristol-Myers Squibb

Investigator Role:

Study Director

Investigator Affiliation:

Bristol-Myers Squibb


United States: Food and Drug Administration

Study ID:




Start Date:

May 2011

Completion Date:

June 2014

Related Keywords:

  • Renal Cell Carcinoma
  • Advanced/Metastatic
  • clear cell component
  • Carcinoma
  • Carcinoma, Renal Cell



Roswell Park Cancer Institute Buffalo, New York  14263
Memorial Sloan-Kettering Cancer Center New York, New York  10021
Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
Medical University of South Carolina Charleston, South Carolina  29425-0721
Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Loyola University Medical Center Maywood, Illinois  60153
University of Kansas Medical Center Kansas City, Kansas  66160-7353
Mount Sinai Medical Center New York, New York  10029
Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire  03756
Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana  46202-5289
University of Colorado Denver, Colorado  80217
Stanford Cancer Center Stanford, California  94305-5824
Seattle Cancer Care Alliance Seattle, Washington  98109
University of Pennsylvania Philadelphia, Pennsylvania  19104
Duke University Medical Center Durham, North Carolina  27710
University of Michigan Medical Center Ann Arbor, Michigan  48104-0914
Cleveland Clinic Cleveland, Ohio  44195
Wayne State University Detroit, Michigan  48202
University of Maryland Baltimore, Maryland  21201
Blumenthal Cancer Center Charlotte, North Carolina  28203
Georgetown University Medical Center Washington, District of Columbia  20007
UCLA Los Angeles, California  90095
UCSD Moores Cancer Center La Jolla, California  93093
Northwestern University Feinberg School of Medicine Chicago, Illinois  60611
Tennessee Oncology, PLLC Clarksville, Tennessee  37043
St. Luke's Roosevelt Hospital Center New York, New York  10019
Weill Cornell Medical College New York, New York  10021
Vanderbilt-Ingram Cancer Ctr Nashville, Tennessee  37232
The Bunting Blaustein Cancer Research Building Baltimore, Maryland  21231
North Mississippi Hematology And Oncology Associates, Ltd Tupelo, Mississippi  38801
Masonic Cancer Ctr, University Of Minnesota Minneapolis, Minnesota  55455
Samuel Oschin Comprehensive Cancer Inst. Los Angeles, California  90048
Wheaton Franciscan Health Care Wauwatosa, Wisconsin  53226
Beth Israel Deaconess Medical Ctr. Boston, Massachusetts  02215